General
Caution is to be exercised in prescribing TENUATE (diethylpropion) or TENUATE (diethylpropion) DOSPAN for patients
with hypertension or with symptomatic cardiovascular disease, including arrhythmias.
TENUATE (diethylpropion) or TENUATE (diethylpropion) DOSPAN should not be administered to patients with severe
hypertension.
Reports suggest that diethylpropion hydrochloride may increase convulsions
in some epileptics. Therefore, epileptics receiving TENUATE (diethylpropion) or TENUATE (diethylpropion) DOSPAN
should be carefully monitored. Titration of dose or discontinuance of TENUATE (diethylpropion)
or TENUATE (diethylpropion) DOSPAN may be necessary.
The least amount feasible should be prescribed or dispensed at one time in
order to minimize the possibility of overdosage.
Laboratory Tests
None
Carcinogenesis, Mutagenesis, and Impairment of Fertility
No long-term animal studies have been done to evaluate diethylpropion hydrochloride
for carcinogenicity. Mutagenicity studies have not been conducted. Animal reproduction
studies have revealed no evidence of impairment of fertility (see Pregnancy).
Pregnancy
Teratogenic Effects: Pregnancy Category B. Reproduction studies
have been performed in rats at doses up to 1.6 times the human dose (based on
mg/m2) and have revealed no evidence of impaired fertility or harm
to the fetus due to diethylpropion hydrochloride. There are, however, no adequate
and well-controlled studies in pregnant women. Because animal reproduction studies
are not always predictive of human response, this drug should be used during
pregnancy only if clearly needed.
Spontaneous reports of congenital malformations have been recorded in humans,
but no causal relationship to diethylpropion has been established.
Non-Teratogenic Effects. Abuse with diethylpropion hydrochloride during
pregnancy may result in withdrawal symptoms in the human neonate.
Nursing Mothers
Since diethylpropion hydrochloride and/or its metabolites have been shown to be excreted in human milk, caution should be exercised when TENUATE (diethylpropion) or TENUATE (diethylpropion) DOSPAN is administered to a nursing woman.
Geriatric Use
Clinical studies of TENUATE (diethylpropion) or TENUATE (diethylpropion) DOSPAN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug in known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Pediatric Use
Since safety and effectiveness in pediatric patients below the age of 16 have not been established, TENUATE (diethylpropion) or TENUATE (diethylpropion) DOSPAN is not recommended for use in pediatric patients 16 years of age and under.
Last reviewed on RxList: 12/21/2007
This monograph has been modified to include the generic and brand name in many instances.